Welcome to our dedicated page for NANOMIX CORPORATION news (Ticker: NNMX), a resource for investors and traders seeking the latest updates and insights on NANOMIX CORPORATION stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NANOMIX CORPORATION's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NANOMIX CORPORATION's position in the market.
Nanomix Corporation (OTCQB: NNMX) announced a new equity investment from Mike Wickham, Managing Director of Woodley Equipment Company, involving the purchase of 59,640 shares at $1.17 each, totaling $70,000. This investment adds to Woodley's prior investments, now totaling $570,000. The partnership focuses on developing diagnostic solutions for the veterinary market leveraging the Nanōmix eLab® system, which provides rapid testing for critical infections such as sepsis. The S1 Panel Cartridge offers results in about 12 minutes, significantly faster than traditional methods. The company aims to enhance its market presence and product development through this collaboration, which includes Woodley's clinical research division.
Nanomix Corporation (OTCQB: NNMX) has appointed Christopher R. Hetterly as its new Chief Financial Officer (CFO), effective January 25, 2023. Hetterly brings over 25 years of financial leadership experience, previously serving as the CFO of Octagos Health and in senior roles at various firms including GE Capital and Wells Fargo. His expertise spans capital raising, corporate development, and high-growth finance environments, having raised over $10 billion for companies like eBay and Netflix. CEO Thomas Schlumpberger expressed confidence in Hetterly's ability to drive the company’s goals in mobile point-of-care diagnostics, particularly in establishing their technology as a standard of care.
Nanomix Corporation (OTCQB: NNMX) has entered into a distribution agreement with Gepa Srl to introduce its mobile point-of-care diagnostics in Italy. The partnership aims to enhance the management of critical infections, including sepsis, which affects 50 million people globally each year. The Nanōmix eLab® system offers rapid testing with results in approximately 12 minutes, significantly faster than current methods. The S1 Panel Cartridge, designed for diagnosing critical infections, has received CE marking and UK MHRA registration.
Nanomix (OTCQB: NNMX) announced an exclusive distribution agreement with Woodley Equipment Company to develop and distribute the eLab system for veterinary diagnostics outside the U.S. This partnership aims to create species-specific tests for the S1 critical infection panel. The eLab system allows for rapid point-of-care testing, delivering results in approximately 12 minutes. The S1 Panel has CE marking in Europe and MHRA registration in the UK, addressing a significant need in veterinary healthcare, especially for diagnosing sepsis in animals.
Nanomix Corporation (OTCQB: NNMX) has announced a significant multi-region distribution agreement with Mast Group Limited, enhancing the marketing and distribution of its Nanōmix eLab® system in the UK, Germany, France, Ireland, and South Africa. This partnership aims to improve early diagnosis and treatment of sepsis and pneumonia. The eLab® system is a portable diagnostic solution providing timely results and has received CE marking and MHRA registration. This collaboration marks an important expansion for Nanomix within the European market.
Nanomix Corporation (OTCQB: NNMX) announced a new distribution agreement with Diaclinic SpA in Chile to market its Nanōmix eLab system. This mobile diagnostic tool enables rapid, accurate results for critical infections, including sepsis, in approximately 12 minutes. The eLab aims to enhance healthcare delivery by providing point-of-care testing, significantly reducing time-to-diagnosis and improving patient outcomes. With rising global sepsis cases, this collaboration positions Nanomix for expansion in Latin America, targeting both public and private healthcare sectors.
Nanomix Corporation (OTCQB: NNMX) announced a distribution agreement with IPS Genomix to market the Nanōmix eLab® system in the Middle East. IPS will distribute the S1 Panel assay and future products across multiple countries. The eLab system aims to provide rapid diagnostics for critical infections, including sepsis, which impacts 50 million people annually, resulting in around 11 million deaths. The S1 Panel offers results in approximately 12 minutes, significantly faster than traditional methods, and has received CE marking and MHRA registration.
Nanomix Corporation (OTCQB: NNMX) has partnered with Mobility Health to co-develop a Lab Developed Test (LDT) for evaluating COVID-19 antibody levels. The test will be deployed in a mobile lab and aims to enhance patient decisions regarding their COVID-19 protection. The Nanōmix eLab® system provides rapid, cost-effective testing with results available within minutes. The S1 Panel Cartridge has received CE marking in Europe, enabling quicker diagnoses of critical infections. This initiative aligns with both companies' missions to improve healthcare accessibility and diagnostics.
Nanomix Corporation (OTCQB: NNMX) has appointed Dr. Tadd S. Lazarus as an independent director on its Board of Directors. His extensive experience in medical diagnostics is expected to enhance the company's commercialization of its critical infection assay panel and the development of new products, particularly its mobile diagnostics platform, the eLab. The eLab system offers rapid, accurate results for critical conditions, aiding in faster clinical decision-making, which is essential for improving patient outcomes.
Nanomix Corporation (OTCQB: NNMX) has signed a distribution agreement with BIOASIA PTE LTD to market the Nanōmix eLab® system in Singapore and Brunei. This includes the Nanōmix S1 Panel assay, aimed at addressing critical infections like sepsis. The eLab® system offers rapid diagnostic results in approximately 12 minutes, which is crucial in early sepsis detection. Nanomix is optimistic about expanding its presence in Asia, capitalizing on the region's healthcare needs. The S1 Panel has received CE marking and UK MHRA registration, enhancing its marketability.
FAQ
What is the market cap of NANOMIX CORPORATION (NNMX)?
